All In Biotech

Drug Trial Radar · NCT02959580

Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis

Evaluation of Topical Steroids and Surgical Treatment for Idiopathic Granulomatous Mastitis

Last checked: Nov 20, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 1, 2017

Primary completion

Sep 1, 2020

Study completion Sep 2020

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the clinical response rate of topical steroids in the treatment of idiopathic granulomatous mastitis in female adults. Half of the participants will receive topical steroid and the other half will receive local wide surgical excision.

Conditions

  • Granulomatous Mastitis

Interventions

  • Hydrocortisone ButyrateDrug

    topical use

  • extended excisionProcedure

    Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical response rateTime frame: six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Breast Surgery,Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.